Swiss IoT module maker u-blox is to phase out its loss-making cellular IoT business, the firm has said. The division has over 200 employees; jobs are expected to go with its closure. It made revenue ...

Two new cellular agriculture scale-up facilities have opened in the Netherlands, as the country works to strengthen its position as a global leader in the sector and invest in the future of food. The ...

The network is called Lunar Surface Communication System (LSCS), and it is basically a replica of the 4G/LTE cellular technology currently used on a very large scale by the humans of Earth.

(Reuters) - Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the ...

UPDATE 2/9: T-Mobile has since expanded its beta to iPhones running iOS 18.3. And it just revealed in a Super Bowl ad that its cellular Starlink service will launch in July. It'll be free for ...

In his book The Mathematical Universe, mathematician William Dunham wrote of John Venn’s namesake legacy, the Venn diagram, “No one in the long history of mathematics ever became better known ...

This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in ...

8, 2024. (AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

(RTTNews) - Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...

Intra-Cellular Therapies (ITCI) shares soared 14.9% in the last trading session to close at $94.87. The move was backed by solid volume with far more shares changing hands than in a normal session.